Tenderwize
Back to tender search

Open-House Biologics Discount Contract 2025-06 - Pegvisomant

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 282 days left·Open·Supplies
Sign up to saveOpen documents
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-06 - Pegvisomant

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

40 / 100

Complexity

30 / 100

Risk factors

No estimated contract value is provided, making it impossible to assess potential revenue.

This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Provision of Pegvisomant pharmaceutical products under discount contracts
  • Contract term up to 24 months from June 2025
Show full summary

Open-House procedure for pharmaceutical discount contracts (Rabattverträge) for Pegvisomant under §130a Abs. 8 SGB V. Lead buyer: Techniker Krankenkasse, with HEK and hkk as non-lead buyers. Contract runs from 01.06.2025 to 31.05.2027 (max 24 months). All qualified pharmaceutical entrepreneurs can join at any time. No estimated value or award criteria specified; procedure is non-competitive.

Risks

No estimated contract value is provided, making it impossible to assess potential revenue.

This is not a traditional procurement but an open-house model; legal recourse is through social courts, not procurement...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG for the offered medicinal product
  • Must have a valid marketing authorization for the product in Germany/EU/EEA

Administrative

  • Must submit self-declaration on authorization and reliability (Anlage 4 zum Vertrag)

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Contract 2025-06 - Pegvisomant

Conclusion of drug discount contracts for the active substance Pegvisomant via an Open-House procedure. No exclusivity; all eligible pharmaceutical entrepreneurs can participate.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

May 2025 - May 2027

Category

Pharmaceutical products

Deadline

Deadline May 31, 2027

Procurement Details

Publication date
08 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
229307-2025

Documents (1)

Procurement document 1

Similar tenders

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

France – Pharmaceutical products – 26-10 : ACCORD-CADRE DE FOURNITURE DE MÉDICAMENTS 2026

Aug 21

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9